Information for "A new Period Two Trial involving Osimertinib since the FirstLine Treating NonSmall Cellular Cancer of the lung Harboring Initiating EGFR Mutations inside Circulating Growth Genetic makeup LiquidLungOCohort 1"
From EECH Central
Basic information
| Display title | A new Period Two Trial involving Osimertinib since the FirstLine Treating NonSmall Cellular Cancer of the lung Harboring Initiating EGFR Mutations inside Circulating Growth Genetic makeup LiquidLungOCohort 1 |
| Default sort key | A new Period Two Trial involving Osimertinib since the FirstLine Treating NonSmall Cellular Cancer of the lung Harboring Initiating EGFR Mutations inside Circulating Growth Genetic makeup LiquidLungOCohort 1 |
| Page length (in bytes) | 3,245 |
| Page ID | 1339877 |
| Page content language | English (en) |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
Page protection
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
Edit history
| Page creator | Jarstop14 (Talk | contribs) |
| Date of page creation | 11:26, 5 April 2024 |
| Latest editor | Jarstop14 (Talk | contribs) |
| Date of latest edit | 11:26, 5 April 2024 |
| Total number of edits | 1 |
| Total number of distinct authors | 1 |
| Recent number of edits (within past 90 days) | 1 |
| Recent number of distinct authors | 1 |
